Clinical trial · Observational
Study In Patients With Kidney Cancer Treated With Sutent
Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent
NCT00873210CI-TRIAL-00008449completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced or Metastatic Renal Cell Carcinoma | — | UNRESOLVED | — |
| Renal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sutent | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Patients treated with Sutent
- description
- 125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
- interventionNames
- Drug: Sutent
Primary outcomes (1)
- measure
- Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
- timeFrame
- 36 months
Secondary outcomes (5)
- measure
- Dose modifications
- timeFrame
- 36 months
- measure
- Incidence of new diagnosed hypertension
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy Exclusion Criteria: * Hypersensitivity to sunitinib malate or to any of the excipients * Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).
References
Publications (0)
Data not yet available
No reference posted for this study.